Avonex
Sponsors
National Institute of Allergy and Infectious Diseases (NIAID), Genentech, Inc., Biogen, Trinity Health Of New England, Biocad
Conditions
HealthyHealthy VolunteersMultiple SclerosisMultiple Sclerosis, Relapsing-RemittingRelapsing-remitting Multiple SclerosisUlcerative Colitis
Phase 1
A Study of Avonex to Determine the Effects of Dose Titration on the Incidence of Flu Like Symptoms in Healthy Volunteers
CompletedNCT01119677
Start: 2010-05-05End: 2010-10-23Updated: 2017-11-17
A Multiple-Dose, Open-Label, Phase 1, Pharmacokinetic, Pharmacodynamic, and Safety Study of Avonex® in Chinese Healthy Volunteer Subjects
CompletedNCT01416207
Start: 2011-08-31End: 2011-10-31Updated: 2011-11-04
Open Label Study of Tolerability, Pharmacokinetics and Pharmacodynamics of BCD-054 (Pegylated Interferon Beta-1a), IM and SC, Compared to Rebif® and Avonex® in Healthy Volunteers
CompletedNCT02359877
Start: 2014-07-31End: 2015-12-31Updated: 2017-04-10
Immune- and miRNA-response to Recombinant Interferon Beta in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis
NCT02364986
Start: 2015-01-31End: 2017-01-31Target: 50Updated: 2016-06-03
Phase 2
Interferon-beta1a (AVONEX) Treatment of Ulcerative Colitis
CompletedNCT00048347
Start: 2002-10-31End: 2010-05-31Updated: 2010-09-08
A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis
CompletedNCT00676715
Start: 2008-07-17End: 2023-11-08Updated: 2024-12-31
Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex
CompletedNCT01864148
Start: 2013-08-31End: 2016-03-31Updated: 2017-05-03